<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649411</url>
  </required_header>
  <id_info>
    <org_study_id>KRX-0502-309</org_study_id>
    <nct_id>NCT04649411</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease</brief_title>
  <official_title>A 24-Week, Open-Label, Randomized, 2-Arm Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keryx Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keryx Biopharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety and tolerability of ferric citrate in&#xD;
      pediatric participants with iron deficiency anemia (IDA) associated with non-dialysis&#xD;
      dependent chronic kidney disease (NDD-CKD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2022</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-serious Treatment-emergent Adverse Events</measure>
    <time_frame>up to Week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinically Significant Laboratory Abnormalities or Changes in Laboratory Results</measure>
    <time_frame>up to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events Leading to the Discontinuation of Ferric Citrate</measure>
    <time_frame>up to Week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin to Week 24/Early Termination Visit</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Transferrin Saturation (TSAT) to Week 24/Early Termination Visit</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ferritin to Week 24/Early Termination Visit</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Serum Phosphorus to Week 24/Early Termination Visit</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Calcium to Week 24/Early Termination Visit</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bicarbonate to Week 24/Early Termination Visit</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ferric citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to &lt;18 years and 6 to &lt;12 years will receive ferric citrate for 24 weeks at a starting dose based on body weight categories.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 12 to &lt;18 years and 6 to &lt;12 years will receive standard of care treatment for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric citrate</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>Ferric citrate</arm_group_label>
    <other_name>KRX-0502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>administered per the approved label and at the Investigator's discretion</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 years to &lt;18 years at Screening&#xD;
&#xD;
          -  Body Weight ≥12 kilograms (kg) at Screening&#xD;
&#xD;
          -  Chronic kidney disease (CKD) stage 3 to 5, not on dialysis, with estimated glomerular&#xD;
             filtration rate (eGFR) &lt;60 milliliters per minute (mL/min)/1.73 meters squared (m^2)&#xD;
             utilizing the &quot;Bedside Schwartz&quot; equation&#xD;
&#xD;
          -  Hemoglobin (Hgb) ≥8.5 and ≤11.5 grams per deciliter (g/dL) at Screening&#xD;
&#xD;
          -  Transferrin saturation (TSAT) ≤25% at Screening&#xD;
&#xD;
          -  Ferritin ≤200 nanograms per milliliter (ng/mL) at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum phosphorus level at Screening:&#xD;
&#xD;
               -  6 to &lt;13 years: ≤4.0 milligrams per deciliter (mg/dL);&#xD;
&#xD;
               -  13 to &lt;18 years: ≤2.7 mg/dL&#xD;
&#xD;
          -  Liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase&#xD;
             [ALT]) ˃3× the upper limit of normal at Screening&#xD;
&#xD;
          -  Active significant gastrointestinal (GI) disorder, including overt gastrointestinal&#xD;
             (GI) bleeding or active inflammatory bowel disease&#xD;
&#xD;
          -  Unable to swallow pills&#xD;
&#xD;
          -  Anemia due to causes other than iron deficiency anemia (IDA) of CKD&#xD;
&#xD;
          -  Intravenous iron therapy or blood transfusion within 4 weeks before the Screening&#xD;
             visit&#xD;
&#xD;
          -  Participants with a functioning organ transplant&#xD;
&#xD;
          -  Receipt of any investigational drug within 4 weeks before Screening&#xD;
&#xD;
          -  Phosphate binder use during the Screening period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akebia Medical Information</last_name>
    <phone>844-445-3799</phone>
    <email>medicalinfo@akebia.com</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron Deficiency Anemia</keyword>
  <keyword>Non-Dialysis Dependent Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>ferric citrate</keyword>
  <keyword>pediatric</keyword>
  <keyword>dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

